10,941 results on '"Carvedilol"'
Search Results
2. Endoscopic Variceal Ligation vs Carvedilol for the Prevention of First Esophageal Variceal Bleeding in Patients With HCC (P-HCC-CVL)
3. Pharmacological Reduction of Right Ventricular Enlargement (PROVE)
4. Non-selective Beta-blocker in Compensated Advanced Chronic Liver Disease (BB_cACLD)
5. KF2022#4-trial: Effects of a Beta Blocker and NSAID on CYP Mediated Drug Metabolism (KF2022#4)
6. Carvedilol (25 mg) in 24 Fed, Healthy, Adult Subjects
7. Carvedilol 25 mg in 36 Fasted, Healthy, Adult Subjects
8. Carvedilol + Simvastatin vs. Carvedilol Alone for Cirrhosis and Cirrhotic Cardiomyopathy and Impact on Hepatic Decompensation and Survival (CIRROSTAT)
9. TREatment With Beta-blockers After myOcardial Infarction withOut Reduced Ejection fracTion'
10. Effects of Carvedilol on Cardiotoxicity in Cancer Patients Submitted to Anthracycline Therapy (CardioTox)
11. The Efficacy and Safety of Alverine in the Treatment of Portal Hypertension in Patients With Liver Cirrhosis
12. A Prospective Study of Breast Cancer Patients With Abnormal Strain Imaging
13. CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes (BRAVO)
14. LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED)
15. Acute Hemodynamic Response to Carvedilol in Children With Clinically Significant Portal Hypertension.
16. Lower doses of carvedilol in Japanese heart failure patients with reduced ejection fraction could show the potential to be non-inferior to higher doses in US patients: An international collaborative observational study.
17. Fasting Study of Carvedilol Tablets 12.5 mg to Coreg® Tablets 12.5 mg
18. Clinical Study Evaluating the Effect of Carvedilol in Patients With Active Rheumatoid Arthritis
19. S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
20. Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI.
21. Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors
22. Pilot Deprescribing N-of-1 Trials for Beta-blockers in HFpEF
23. Colchicine Versus Beta-blockers, Angiotensin-converting Enzyme Inhibitors, and Statins for Prevention of Chemotherapy-Induced Cardiomyopathy (BASiC-CIC)
24. Effect of Long-term Carvedilol to Prevent Decompensation or Death in Patients With Asymptomatic Child-Pugh A5 to B8 Cirrhosis and Clinically Significant Portal Hypertension: a Multicenter Double-blind Randomized Control Trial (CARVECIR)
25. Carvedilol inhibits neuronal hyperexcitability caused by epilepsy‐associated KCNT1 mutations.
26. Characterization and Crystal Structural Analysis of Novel Carvedilol Adipate and Succinate Ethanol-Solvated Salts.
27. Development and Validation of a Novel Analytical Method (Ion Pair HPLC) For Separating and Determining Bisoprolol Fumarate and Carvedilol in Pure and Their Pharmaceutical Forms.
28. Early initiation of oral beta-blocker improves long-term survival in patients with acute myocardial infarction who underwent primary percutaneous coronary intervention.
29. Rerouting cardiovascular management following gastric bypass surgery: Dose optimization of carvedilol using population‐based analysis.
30. Risk assessment based on spectrophotometric signals used in eco-friendly analytical scenarios for estimation of carvedilol and hydrochlorothiazide in pharmaceutical formulation.
31. Carvedilol suppresses ryanodine receptor-dependent Ca2+ bursts in human neurons bearing PSEN1 variants found in early onset Alzheimer's disease.
32. Amorphous Solid Dispersions: Implication of Method of Preparation and Physicochemical Properties of API and Excipients.
33. Effect of carvedilol on pharmacokinetics of sofosbuvir and its metabolite GS-331007: role of P-glycoprotein.
34. Real world prescription of beta‐blockers in patients with asthma.
35. Risk assessment based on spectrophotometric signals used in eco-friendly analytical scenarios for estimation of carvedilol and hydrochlorothiazide in pharmaceutical formulation
36. TrAstuzumab Cardiomyopathy Therapeutic Intervention With Carvedilol (TACTIC)
37. Determination of Drug Levels for Pharmacotherapy of Heart Failure
38. Adrenergic Blockers for Cardiac Changes in Early Parkinson's Disease (Protocol 53136)
39. Comparison of Blood Pressure Medications on Metabolism
40. Danish Trial of Beta Blocker Treatment After Myocardial Infarction Without Reduced Ejection Fraction (DANBLOCK)
41. Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart (BORG)
42. Carvedilol in HF With Preserved EF
43. Ascites affects the benefit of carvedilol on patients with liver cirrhosis and esophageal and gastric varices.
44. Harnessing adrenergic blockade in stress-promoted TNBC in vitro and solid tumor in vivo: disrupting HIF-1α and GSK-3β/β-catenin driven resistance to doxorubicin.
45. Carvedilol attenuates inflammatory reactions of lipopolysaccharide-stimulated BV2 cells and modulates M1/M2 polarization of microglia via regulating NLRP3, Notch, and PPAR-γ signaling pathways.
46. M2-type macrophage membrane-mediated delivery of Carvedilol nanocomplex for acute liver failure treatment and remodeling inflammatory microenvironment.
47. Carvedilol increases seizure resistance in a mouse model of SCN8A-derived epilepsy.
48. The influence of drug-induced metabolic enzyme activity inhibition and CYP3A4 gene polymorphism on aumolertinib metabolism.
49. Stability-Indicating UPLC-PDA-QDa Methodology for Carvedilol and Felodipine in Fixed-Dose Combinations Using AQbD Principles.
50. The potential for improved outcomes in the prevention and therapy of diabetic kidney disease through 'stacking' of drugs from different classes.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.